Table I.
IL-17–induced up-regulation of cytokines and chemokines in SMCs
| Transcript | Microarray (fold increase) | qPCR (fold increase) | Inhibited by cycloheximide |
|---|---|---|---|
| BMP2 | 4.4/3.9 | 2.5 | Yes |
| CCL20 | 5.5 | 7.7 | No |
| CXCL1 | 2.2 | 13.7 | No |
| CXCL3 | 4.9 | 7.9 | No |
| IL-1β | 2.6/2.6 | 11.1 | No |
| IL-6 | 2.8 | 4.4 | No |
| CXCL8 | 2.5/3.3 | 17.2 | No |
| IL-11 | 20.8/3.6 | 3.7 | Yes |
| LIF | 4.1 | 2.7 | No |
SMCs were treated with 100 ng/ml IL-17 for 6 h in three independent experiments using different donors. The mean fold change of cytokine and chemokine transcript expression in response to IL-17 treatment was assessed by microarray (certain cytokines were represented by more than one probe) and quantitative RT-PCR (qPCR). Transcripts for which IL-17–mediated up-regulation was not diminished by 10 μg/ml cycloheximide, as assessed by RT-PCR, were considered primary gene targets.